Disclosed are conjugates which bind VLA-4. Certain of these conjugates
also inhibit leukocyte adhesion and, in particular, leukocyte adhesion
mediated by VLA-4. Such conjugates are useful in the treatment of
inflammatory diseases in a mammalian patient, e.g., human, such as
asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes,
inflammatory bowel disease, rheumatoid arthritis, tissue transplantation,
tumor metastasis and myocardial ischemia. The conjugates can also be
administered for the treatment of inflammatory brain diseases such as
multiple sclerosis.